Cantor Fitzgerald Starts Coverage on Aquestive Therapeutics with Positive Rating

On Tuesday, analysts at Cantor Fitzgerald announced the initiation of coverage on shares of Aquestive Therapeutics (NASDAQ:AQST). They have assigned an "overweight" rating to the stock, reflecting a strong optimistic outlook. Additionally, Cantor Fitzgerald set a price target of $17.00 for the shares, suggesting a substantial potential upside of 372.22% based on the stock's previous closing price.

Analyst Reports and Ratings

Following Cantor Fitzgerald's report, other research firms have also issued their insights on Aquestive Therapeutics. For instance, Leerink Partners raised their price objective for the company from $12.00 to $13.00, giving it an "outperform" rating in a recent report. HC Wainwright maintained a "buy" rating while assigning a $10.00 price target. Meanwhile, JMP Securities characterized the stock as "market outperform" with a price objective of $9.00 in a note shortly after. Overall, six analysts have rated Aquestive Therapeutics with a buy rating, and one has given it a strong buy, resulting in a consensus rating of "Buy" with a target price averaging around $11.00.

Aquestive Therapeutics Stock Performance

As of Tuesday, shares of Aquestive Therapeutics opened at $3.60. The stock has experienced fluctuations, reaching a twelve-month low of $1.84 and a high of $6.23. The company has a 50-day moving average price of $4.83 and a 200-day moving average price of $4.06, with a market capitalization of approximately $328.24 million. The firm's price-to-earnings ratio stands at -8.00, with a beta of 2.62, indicating volatility compared to the market.

Latest Earnings Announcement

Recently, Aquestive Therapeutics reported its quarterly earnings on November 4th. The company disclosed earnings per share of ($0.13), which did not meet analysts' expectations of ($0.12) by a small margin. Their revenue for the quarter was reported at $13.54 million, slightly above the forecast of $12.69 million. In the same quarter of the previous year, the earnings per share were ($0.03). Analysts now forecast that Aquestive Therapeutics will report an EPS of -0.47 for the current fiscal year.

Institutional Investors Activity

In recent months, several institutional investors and hedge funds have adjusted their holdings in Aquestive Therapeutics. State Street Corp has increased its stake by 52.1%, owning over 1.49 million shares valued at about $7.45 million after acquiring an additional 512,682 shares. Similarly, Blue Owl Capital Holdings LP raised its holdings by 30.3%, now owning 1.14 million shares worth nearly $2.96 million. Other firms, including Bank of New York Mellon and Verition Fund Management, have established new positions in the company. Currently, institutional investors collectively hold about 32.45% of the stock.

Aquestive Therapeutics Overview

Aquestive Therapeutics, operating as a pharmaceutical company, provides innovative drug delivery solutions. The company markets various products, including Sympazan, an oral film formulation of clobazam for treating Lennox-Gastaut syndrome, and Suboxone, a sublingual film for opioid dependence. Other offerings are Zuplenz, for nausea and vomiting associated with chemotherapy, and Azstarys, a once-daily treatment for attention deficit hyperactivity disorder.

Stocks, Investors, Analysis